+Follow
曹环球
No personal profile
99
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
曹环球
2021-02-16
Okie
Zhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572831909828511","uuid":"3572831909828511","gmtCreate":1609739061755,"gmtModify":1612234441408,"name":"曹环球","pinyin":"chqcaohuanqiu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":99,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":382669879,"gmtCreate":1613442259491,"gmtModify":1704880487488,"author":{"id":"3572831909828511","authorId":"3572831909828511","name":"曹环球","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572831909828511","authorIdStr":"3572831909828511"},"themes":[],"htmlText":"Okie ","listText":"Okie ","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382669879","repostId":"2111004080","repostType":4,"repost":{"id":"2111004080","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613431692,"share":"https://ttm.financial/m/news/2111004080?lang=en_US&edition=fundamental","pubTime":"2021-02-16 07:28","market":"hk","language":"zh","title":"Zhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200","url":"https://stock-news.laohu8.com/highlight/detail?id=2111004080","media":"老虎资讯综合","summary":"2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元可购买的一定数目的发售股份。","content":"<p>News on February 16,<a href=\"https://laohu8.com/S/603127\">Zhaoyan New Drug</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>In the IPO from February 16 to February 19, 2021, the company plans to issue 43.3248 million shares, with Hong Kong public offering accounting for 10%, international offering accounting for 90%, and 15% over-allotment option. HK $133-151 per share, 100 shares per lot. It is expected that H shares will start trading in Hong Kong at 9:00 a.m. on February 26, 2021.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>There are 100 shares per lot, and the admission fee is about HK $15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK $6,1008,65.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on the non-clinical safety evaluation of drugs, and is expanding to provide comprehensive services covering the drug discovery, preclinical and clinical trial phases along the drug development service chain. The company's non-clinical research refers to drug research and development research, not clinical trials conducted with human subjects. These non-clinical studies cover all important stages of the drug discovery process, including drug discovery, preclinical and clinical trial stages.</p><p>The company is a domestic contract research organization specializing in pharmacological and toxicological research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization for drug non-clinical safety evaluation in China. In terms of revenue in 2019, The market share is 15.7%. In 2019, the market size of China and the global drug non-clinical safety contract research organization market was US $416 million and US $4.8 billion respectively, accounting for approximately US $6.8 billion and US $62.6 billion respectively in the market size of China and the global pharmaceutical contract research organization market in 2019. 6.1% and 7.7%. The company's A shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>Headquartered in Beijing, the company currently owns and operates two GLP certification facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total construction area of approximately 11,600 square meters. The company's facilities in Suzhou have a total construction area of approximately 61,600 square meters, and the company plans to start construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>In order to further expand service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with bioanalytical service-related platforms in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory in Chongqing. Experimental model breeding facility and clinical research central laboratory. The Company expects the first phase of these facilities to be operational in 2023. In addition to facilities in China, the company has been expanding the company's global footprint through endogenous growth and strategic acquisitions. The company acquired Biomere in 2019, a professional contract research organization engaged in pharmaceutical discovery located in Worcester, Massachusetts. It has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB 158 million, accounting for 25% of the company's total revenue and accounting for most of the company's overseas revenue during the same period. Together with the company's planned lease and upgrade of facilities in Northern California in the near future, the company aims to establish a strategic layout on the east and west coasts of the United States, so that the company's U.S. facilities are located adjacent to two famous life science centers in the United States.</p><p>During the Track Record Period, the company's business and profitability both achieved large-scale and strong growth. The company's total revenue increased from RMB 301 million in 2017 to RMB 409 million in 2018, and further increased to RMB 639 million in 2019, with a compound annual growth rate of 45.7%. Profit for the year increased from RMB 79.9 million in 2017 to RMB 105 million in 2018, and further increased to RMB 188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed to subscribe for a certain number of Offer Shares that can be purchased for a total of US $26.8 billion (approximately HK $2.078 billion) at the Offer Price subject to certain conditions. Assuming that the Offer Price is HK $142 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed for by cornerstone investors will be 14.6318 million Offer Shares, accounting for approximately the number of H shares offered under the Global Offering. 33.8% and 5.4% of the company's total issued share capital immediately after the completion of the Global Offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders Janchor Partners, Valliance Fund, CPE Fund and ICBCCS (held on behalf of the China Structural Adjustment Fund) have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime managed by Qingchi Capital (Hong Kong) Co., Ltd.; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Sequoia Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming the offer price is HK $142.00, the net raising will be HK $5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthens the company's U.S. business to cater to the growing customer demand for the services provided by Biomere. About 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. About 5% expanded and deepened the company's comprehensive contract research organization services, with special emphasis on further expanding the company's clinical trials and related services. Approximately 20% provides funds for suitable contract research organizations focusing on non-clinical research, contract research organizations focusing on clinical trials, and potential acquisitions of experimental model production facilities in China and overseas to further implement the company's expansion in the next one to three years The strategy of comprehensive service scope along the drug R&D value chain and expanding overseas layout. Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-16 07:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>News on February 16,<a href=\"https://laohu8.com/S/603127\">Zhaoyan New Drug</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>In the IPO from February 16 to February 19, 2021, the company plans to issue 43.3248 million shares, with Hong Kong public offering accounting for 10%, international offering accounting for 90%, and 15% over-allotment option. HK $133-151 per share, 100 shares per lot. It is expected that H shares will start trading in Hong Kong at 9:00 a.m. on February 26, 2021.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>There are 100 shares per lot, and the admission fee is about HK $15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK $6,1008,65.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on the non-clinical safety evaluation of drugs, and is expanding to provide comprehensive services covering the drug discovery, preclinical and clinical trial phases along the drug development service chain. The company's non-clinical research refers to drug research and development research, not clinical trials conducted with human subjects. These non-clinical studies cover all important stages of the drug discovery process, including drug discovery, preclinical and clinical trial stages.</p><p>The company is a domestic contract research organization specializing in pharmacological and toxicological research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization for drug non-clinical safety evaluation in China. In terms of revenue in 2019, The market share is 15.7%. In 2019, the market size of China and the global drug non-clinical safety contract research organization market was US $416 million and US $4.8 billion respectively, accounting for approximately US $6.8 billion and US $62.6 billion respectively in the market size of China and the global pharmaceutical contract research organization market in 2019. 6.1% and 7.7%. The company's A shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>Headquartered in Beijing, the company currently owns and operates two GLP certification facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total construction area of approximately 11,600 square meters. The company's facilities in Suzhou have a total construction area of approximately 61,600 square meters, and the company plans to start construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>In order to further expand service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with bioanalytical service-related platforms in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory in Chongqing. Experimental model breeding facility and clinical research central laboratory. The Company expects the first phase of these facilities to be operational in 2023. In addition to facilities in China, the company has been expanding the company's global footprint through endogenous growth and strategic acquisitions. The company acquired Biomere in 2019, a professional contract research organization engaged in pharmaceutical discovery located in Worcester, Massachusetts. It has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB 158 million, accounting for 25% of the company's total revenue and accounting for most of the company's overseas revenue during the same period. Together with the company's planned lease and upgrade of facilities in Northern California in the near future, the company aims to establish a strategic layout on the east and west coasts of the United States, so that the company's U.S. facilities are located adjacent to two famous life science centers in the United States.</p><p>During the Track Record Period, the company's business and profitability both achieved large-scale and strong growth. The company's total revenue increased from RMB 301 million in 2017 to RMB 409 million in 2018, and further increased to RMB 639 million in 2019, with a compound annual growth rate of 45.7%. Profit for the year increased from RMB 79.9 million in 2017 to RMB 105 million in 2018, and further increased to RMB 188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed to subscribe for a certain number of Offer Shares that can be purchased for a total of US $26.8 billion (approximately HK $2.078 billion) at the Offer Price subject to certain conditions. Assuming that the Offer Price is HK $142 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed for by cornerstone investors will be 14.6318 million Offer Shares, accounting for approximately the number of H shares offered under the Global Offering. 33.8% and 5.4% of the company's total issued share capital immediately after the completion of the Global Offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders Janchor Partners, Valliance Fund, CPE Fund and ICBCCS (held on behalf of the China Structural Adjustment Fund) have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime managed by Qingchi Capital (Hong Kong) Co., Ltd.; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Sequoia Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming the offer price is HK $142.00, the net raising will be HK $5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthens the company's U.S. business to cater to the growing customer demand for the services provided by Biomere. About 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. About 5% expanded and deepened the company's comprehensive contract research organization services, with special emphasis on further expanding the company's clinical trials and related services. Approximately 20% provides funds for suitable contract research organizations focusing on non-clinical research, contract research organizations focusing on clinical trials, and potential acquisitions of experimental model production facilities in China and overseas to further implement the company's expansion in the next one to three years The strategy of comprehensive service scope along the drug R&D value chain and expanding overseas layout. Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"603127":"昭衍新药","06127":"昭衍新药","000860.SH":"结构调整"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111004080","content_text":"2月16日消息，昭衍新药$(06127)$于2021年2月16日-2月19日招股，公司拟发行4332.48万股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股133-151港元，每手100股，预期H股将在香港于2021年2月26日上午九时正开始买卖。申购阶梯：每手100股，入场费约15252.17港元。乙组门槛为4万股，申购所需资金约6100865.08港元。公司是一家专注于药物非临床安全性评价的领先合同研究组织，正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。公司的非临床研究指药物研发研究，并非以人为受试对象进行的临床试验。该等非临床研究涵盖药物研发过程的所有重要阶段，包括药物发现、临床前及临床试验阶段。公司是国内专门从事新药药理毒理学研究的合同研究组织，根据弗若斯特沙利文的资料，现在公司已成为国内最大的药物非临床安全性评价合同研究组织，按2019年的收益计，市场份额为15.7%。2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。公司A股自 2017年8月起已于上海证券交易所上市(股票代码：603127)。公司的总部位于北京，目前在国内拥有及经营两家GLP认证设施，位于北京及苏州，具有战略意义。根据弗若斯特沙利文的资料，按符合GLP设施的规模计，公司是中国领先的合同研究组织。公司位于北京的设施总建筑面积约11,600平方米。公司位于苏州的设施总建筑面积约61,600平方米，且公司计划于2021年开工建设约20,000平方米的额外实验室及实验模型设施。为进一步扩大服务能力及地理覆盖范围，公司亦正计划在广州建立一个创新药的药物安全评价中心及配备生物分析服务相关平台的中央实验室，及在重庆建立符合GLP的非临床研究实验室、实验模型繁殖设施及临床研究中央实验室。公司预计该等设施一期将于2023年投入运营。除在中国的设施外，公司一直透过内生增长及策略性收购扩阔公司的全球版图。公司于2019年收购Biomere，一个位于马萨诸塞州伍斯特市从事医药发现的专业合同研究组织，其拥有国际客户基础且在客户服务方面拥有良好声誉。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。连同公司计划近期租赁及升级的位于北加利福尼亚州的设施，公司旨在于美国东西海岸确立具有战略意义的布局，使公司的各美国设施所处位置毗邻美国两大着名生命科学中心。于往绩记录期，公司的业务及盈利能力双双实现大规模有力增长。公司的总收益由2017年的人民币3.01亿元增至2018年的人民币4.09亿元，并进一步增至2019 年的人民币6.39亿元，复合年增长率为45.7%。年内利润由2017年的人民币7990万元增至2018年的人民币1.05亿元，并进一步增至2019年的人民币1.88亿元，复合年增长率为53.2%。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元(约20.78亿港元)可购买的一定数目的发售股份。假设发售价为142港元(即发售价范围的中位数)，则基石投资者将予认购的发售股份总数将为1463.18万股发售股份，约占根据全球发售提呈发售的H股数目的33.8%及紧随全球发售完成后公司已发行股本总额的5.4%。公司的现有股东Janchor Partners、Valliance Fund、CPE Fund及ICBCCS(代表中国结构调整基金持有)已获准参与基石配售。此外，基石投资者总共10个，包括由清池资本(香港)有限公司管理的Lake Bleu Prime;OrbiMed基金;中国结构调整基金;由源峰基金管理的CPE Fund;Sequoia Capital China Growth;Janchor Partners Pan-Asian Master Fund;CRF;Carmignac基金;Octagon Capital;Valliance Fund。假设发售价为142.00港元，净筹59.1亿港元。约16%将用于翻新现有设备及设施，建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员，以提高公司苏州设施的非临床研究产能。约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求。约39%将用于在广州及重庆建设新设施，雇佣经验丰富的专业人员，及发展尖端技术，进一步扩大公司于中国的设施网络及服务能力。约5%拓展及深化公司的综合合同研究组织服务，特别着重于进一步扩展公司的临床试验及相关服务。约20%为合适的专注于非临床研究的合同研究组织，专注于临床试验的合同研究组织及中国及海外的实验模型生产设施的潜在收购提供资金，以于未来一至三年内进一步实施公司拓宽药物研发价值链上的综合服务范围并拓展海外布局的策略。约10%将用于营运资金及一般企业用途。","news_type":1,"symbols_score_info":{"603127":0.9,"06127":0.9,"000860.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":382669879,"gmtCreate":1613442259491,"gmtModify":1704880487488,"author":{"id":"3572831909828511","authorId":"3572831909828511","name":"曹环球","avatar":"https://static.tigerbbs.com/ce307788b7898a4fbe10c5f18c696846","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572831909828511","idStr":"3572831909828511"},"themes":[],"htmlText":"Okie ","listText":"Okie ","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382669879","repostId":"2111004080","repostType":4,"repost":{"id":"2111004080","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1613431692,"share":"https://ttm.financial/m/news/2111004080?lang=en_US&edition=fundamental","pubTime":"2021-02-16 07:28","market":"hk","language":"zh","title":"Zhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200","url":"https://stock-news.laohu8.com/highlight/detail?id=2111004080","media":"老虎资讯综合","summary":"2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元可购买的一定数目的发售股份。","content":"<p>News on February 16,<a href=\"https://laohu8.com/S/603127\">Zhaoyan New Drug</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>In the IPO from February 16 to February 19, 2021, the company plans to issue 43.3248 million shares, with Hong Kong public offering accounting for 10%, international offering accounting for 90%, and 15% over-allotment option. HK $133-151 per share, 100 shares per lot. It is expected that H shares will start trading in Hong Kong at 9:00 a.m. on February 26, 2021.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>There are 100 shares per lot, and the admission fee is about HK $15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK $6,1008,65.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on the non-clinical safety evaluation of drugs, and is expanding to provide comprehensive services covering the drug discovery, preclinical and clinical trial phases along the drug development service chain. The company's non-clinical research refers to drug research and development research, not clinical trials conducted with human subjects. These non-clinical studies cover all important stages of the drug discovery process, including drug discovery, preclinical and clinical trial stages.</p><p>The company is a domestic contract research organization specializing in pharmacological and toxicological research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization for drug non-clinical safety evaluation in China. In terms of revenue in 2019, The market share is 15.7%. In 2019, the market size of China and the global drug non-clinical safety contract research organization market was US $416 million and US $4.8 billion respectively, accounting for approximately US $6.8 billion and US $62.6 billion respectively in the market size of China and the global pharmaceutical contract research organization market in 2019. 6.1% and 7.7%. The company's A shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>Headquartered in Beijing, the company currently owns and operates two GLP certification facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total construction area of approximately 11,600 square meters. The company's facilities in Suzhou have a total construction area of approximately 61,600 square meters, and the company plans to start construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>In order to further expand service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with bioanalytical service-related platforms in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory in Chongqing. Experimental model breeding facility and clinical research central laboratory. The Company expects the first phase of these facilities to be operational in 2023. In addition to facilities in China, the company has been expanding the company's global footprint through endogenous growth and strategic acquisitions. The company acquired Biomere in 2019, a professional contract research organization engaged in pharmaceutical discovery located in Worcester, Massachusetts. It has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB 158 million, accounting for 25% of the company's total revenue and accounting for most of the company's overseas revenue during the same period. Together with the company's planned lease and upgrade of facilities in Northern California in the near future, the company aims to establish a strategic layout on the east and west coasts of the United States, so that the company's U.S. facilities are located adjacent to two famous life science centers in the United States.</p><p>During the Track Record Period, the company's business and profitability both achieved large-scale and strong growth. The company's total revenue increased from RMB 301 million in 2017 to RMB 409 million in 2018, and further increased to RMB 639 million in 2019, with a compound annual growth rate of 45.7%. Profit for the year increased from RMB 79.9 million in 2017 to RMB 105 million in 2018, and further increased to RMB 188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed to subscribe for a certain number of Offer Shares that can be purchased for a total of US $26.8 billion (approximately HK $2.078 billion) at the Offer Price subject to certain conditions. Assuming that the Offer Price is HK $142 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed for by cornerstone investors will be 14.6318 million Offer Shares, accounting for approximately the number of H shares offered under the Global Offering. 33.8% and 5.4% of the company's total issued share capital immediately after the completion of the Global Offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders Janchor Partners, Valliance Fund, CPE Fund and ICBCCS (held on behalf of the China Structural Adjustment Fund) have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime managed by Qingchi Capital (Hong Kong) Co., Ltd.; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Sequoia Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming the offer price is HK $142.00, the net raising will be HK $5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthens the company's U.S. business to cater to the growing customer demand for the services provided by Biomere. About 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. About 5% expanded and deepened the company's comprehensive contract research organization services, with special emphasis on further expanding the company's clinical trials and related services. Approximately 20% provides funds for suitable contract research organizations focusing on non-clinical research, contract research organizations focusing on clinical trials, and potential acquisitions of experimental model production facilities in China and overseas to further implement the company's expansion in the next one to three years The strategy of comprehensive service scope along the drug R&D value chain and expanding overseas layout. Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoyan New Drug will launch its IPO today, and the admission fee is about HK $15,200\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-02-16 07:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>News on February 16,<a href=\"https://laohu8.com/S/603127\">Zhaoyan New Drug</a><a href=\"https://laohu8.com/S/06127\">$(06127)$</a>In the IPO from February 16 to February 19, 2021, the company plans to issue 43.3248 million shares, with Hong Kong public offering accounting for 10%, international offering accounting for 90%, and 15% over-allotment option. HK $133-151 per share, 100 shares per lot. It is expected that H shares will start trading in Hong Kong at 9:00 a.m. on February 26, 2021.<img src=\"https://static.tigerbbs.com/79818d62c63fd4696523d37ce13c7f9d\" tg-width=\"717\" tg-height=\"587\" referrerpolicy=\"no-referrer\"><b>Subscription ladder:</b></p><p>There are 100 shares per lot, and the admission fee is about HK $15,252.17.</p><p>The threshold for Group B is 40,000 shares, and the funds required for subscription are approximately HK $6,1008,65.08.<img src=\"https://static.tigerbbs.com/1c06bc365ce512a6b3c155fc9ad62a13\" tg-width=\"738\" tg-height=\"445\" referrerpolicy=\"no-referrer\"></p><p>The company is a leading contract research organization focused on the non-clinical safety evaluation of drugs, and is expanding to provide comprehensive services covering the drug discovery, preclinical and clinical trial phases along the drug development service chain. The company's non-clinical research refers to drug research and development research, not clinical trials conducted with human subjects. These non-clinical studies cover all important stages of the drug discovery process, including drug discovery, preclinical and clinical trial stages.</p><p>The company is a domestic contract research organization specializing in pharmacological and toxicological research of new drugs. According to Frost & Sullivan, the company has now become the largest contract research organization for drug non-clinical safety evaluation in China. In terms of revenue in 2019, The market share is 15.7%. In 2019, the market size of China and the global drug non-clinical safety contract research organization market was US $416 million and US $4.8 billion respectively, accounting for approximately US $6.8 billion and US $62.6 billion respectively in the market size of China and the global pharmaceutical contract research organization market in 2019. 6.1% and 7.7%. The company's A shares have been listed on the Shanghai Stock Exchange since August 2017 (stock code: 603127).</p><p>Headquartered in Beijing, the company currently owns and operates two GLP certification facilities in China, located in Beijing and Suzhou, which are of strategic significance. According to Frost & Sullivan, the company is a leading contract research organization in China in terms of the size of its GLP-compliant facilities. The company's facilities in Beijing have a total construction area of approximately 11,600 square meters. The company's facilities in Suzhou have a total construction area of approximately 61,600 square meters, and the company plans to start construction of approximately 20,000 square meters of additional laboratory and experimental model facilities in 2021.</p><p>In order to further expand service capabilities and geographical coverage, the company is also planning to establish a drug safety evaluation center for innovative drugs and a central laboratory equipped with bioanalytical service-related platforms in Guangzhou, and to establish a GLP-compliant non-clinical research laboratory in Chongqing. Experimental model breeding facility and clinical research central laboratory. The Company expects the first phase of these facilities to be operational in 2023. In addition to facilities in China, the company has been expanding the company's global footprint through endogenous growth and strategic acquisitions. The company acquired Biomere in 2019, a professional contract research organization engaged in pharmaceutical discovery located in Worcester, Massachusetts. It has an international customer base and a good reputation for customer service. For the nine months ended September 30, 2020, Biomere generated revenue of RMB 158 million, accounting for 25% of the company's total revenue and accounting for most of the company's overseas revenue during the same period. Together with the company's planned lease and upgrade of facilities in Northern California in the near future, the company aims to establish a strategic layout on the east and west coasts of the United States, so that the company's U.S. facilities are located adjacent to two famous life science centers in the United States.</p><p>During the Track Record Period, the company's business and profitability both achieved large-scale and strong growth. The company's total revenue increased from RMB 301 million in 2017 to RMB 409 million in 2018, and further increased to RMB 639 million in 2019, with a compound annual growth rate of 45.7%. Profit for the year increased from RMB 79.9 million in 2017 to RMB 105 million in 2018, and further increased to RMB 188 million in 2019, representing a CAGR of 53.2%.</p><p>The cornerstone investors have agreed to subscribe for a certain number of Offer Shares that can be purchased for a total of US $26.8 billion (approximately HK $2.078 billion) at the Offer Price subject to certain conditions. Assuming that the Offer Price is HK $142 (i.e. the mid-point of the Offer Price range), the total number of Offer Shares to be subscribed for by cornerstone investors will be 14.6318 million Offer Shares, accounting for approximately the number of H shares offered under the Global Offering. 33.8% and 5.4% of the company's total issued share capital immediately after the completion of the Global Offering.<img src=\"https://static.tigerbbs.com/4eeabccce9601f16c44ab0f537d674ae\" tg-width=\"632\" tg-height=\"633\" referrerpolicy=\"no-referrer\">The company's existing shareholders Janchor Partners, Valliance Fund, CPE Fund and ICBCCS (held on behalf of the China Structural Adjustment Fund) have been approved to participate in the cornerstone placement. In addition, there are a total of 10 cornerstone investors, including Lake Bleu Prime managed by Qingchi Capital (Hong Kong) Co., Ltd.; OrbiMed Fund; China Structural Adjustment Fund; CPE Fund managed by Yuanfeng Fund; Sequoia Capital China Growth; Janchor Partners Pan-Asian Master Fund; CRF; Carmignac Fund; Octagon Capital; Valliance Fund.</p><p>Assuming the offer price is HK $142.00, the net raising will be HK $5.91 billion. Approximately 16% will be used to renovate existing equipment and facilities, establish new experimental model breeding and inventory facilities, and hire experienced professionals to increase the non-clinical research capacity of the company's Suzhou facility. Approximately 10% strengthens the company's U.S. business to cater to the growing customer demand for the services provided by Biomere. About 39% will be used to build new facilities in Guangzhou and Chongqing, hire experienced professionals, and develop cutting-edge technologies to further expand the company's facility network and service capabilities in China. About 5% expanded and deepened the company's comprehensive contract research organization services, with special emphasis on further expanding the company's clinical trials and related services. Approximately 20% provides funds for suitable contract research organizations focusing on non-clinical research, contract research organizations focusing on clinical trials, and potential acquisitions of experimental model production facilities in China and overseas to further implement the company's expansion in the next one to three years The strategy of comprehensive service scope along the drug R&D value chain and expanding overseas layout. Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"603127":"昭衍新药","06127":"昭衍新药","000860.SH":"结构调整"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111004080","content_text":"2月16日消息，昭衍新药$(06127)$于2021年2月16日-2月19日招股，公司拟发行4332.48万股，香港公开发售占10%，国际发售占90%，另有15%超额配股权。每股133-151港元，每手100股，预期H股将在香港于2021年2月26日上午九时正开始买卖。申购阶梯：每手100股，入场费约15252.17港元。乙组门槛为4万股，申购所需资金约6100865.08港元。公司是一家专注于药物非临床安全性评价的领先合同研究组织，正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。公司的非临床研究指药物研发研究，并非以人为受试对象进行的临床试验。该等非临床研究涵盖药物研发过程的所有重要阶段，包括药物发现、临床前及临床试验阶段。公司是国内专门从事新药药理毒理学研究的合同研究组织，根据弗若斯特沙利文的资料，现在公司已成为国内最大的药物非临床安全性评价合同研究组织，按2019年的收益计，市场份额为15.7%。2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元，分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。公司A股自 2017年8月起已于上海证券交易所上市(股票代码：603127)。公司的总部位于北京，目前在国内拥有及经营两家GLP认证设施，位于北京及苏州，具有战略意义。根据弗若斯特沙利文的资料，按符合GLP设施的规模计，公司是中国领先的合同研究组织。公司位于北京的设施总建筑面积约11,600平方米。公司位于苏州的设施总建筑面积约61,600平方米，且公司计划于2021年开工建设约20,000平方米的额外实验室及实验模型设施。为进一步扩大服务能力及地理覆盖范围，公司亦正计划在广州建立一个创新药的药物安全评价中心及配备生物分析服务相关平台的中央实验室，及在重庆建立符合GLP的非临床研究实验室、实验模型繁殖设施及临床研究中央实验室。公司预计该等设施一期将于2023年投入运营。除在中国的设施外，公司一直透过内生增长及策略性收购扩阔公司的全球版图。公司于2019年收购Biomere，一个位于马萨诸塞州伍斯特市从事医药发现的专业合同研究组织，其拥有国际客户基础且在客户服务方面拥有良好声誉。截至2020年9月30日止九个月，Biomere产生收益人民币1.58亿元，占公司总收益的25%并占同期公司绝大部分海外收益。连同公司计划近期租赁及升级的位于北加利福尼亚州的设施，公司旨在于美国东西海岸确立具有战略意义的布局，使公司的各美国设施所处位置毗邻美国两大着名生命科学中心。于往绩记录期，公司的业务及盈利能力双双实现大规模有力增长。公司的总收益由2017年的人民币3.01亿元增至2018年的人民币4.09亿元，并进一步增至2019 年的人民币6.39亿元，复合年增长率为45.7%。年内利润由2017年的人民币7990万元增至2018年的人民币1.05亿元，并进一步增至2019年的人民币1.88亿元，复合年增长率为53.2%。基石投资者已同意在若干条件规限下按发售价认购以合共268亿美元(约20.78亿港元)可购买的一定数目的发售股份。假设发售价为142港元(即发售价范围的中位数)，则基石投资者将予认购的发售股份总数将为1463.18万股发售股份，约占根据全球发售提呈发售的H股数目的33.8%及紧随全球发售完成后公司已发行股本总额的5.4%。公司的现有股东Janchor Partners、Valliance Fund、CPE Fund及ICBCCS(代表中国结构调整基金持有)已获准参与基石配售。此外，基石投资者总共10个，包括由清池资本(香港)有限公司管理的Lake Bleu Prime;OrbiMed基金;中国结构调整基金;由源峰基金管理的CPE Fund;Sequoia Capital China Growth;Janchor Partners Pan-Asian Master Fund;CRF;Carmignac基金;Octagon Capital;Valliance Fund。假设发售价为142.00港元，净筹59.1亿港元。约16%将用于翻新现有设备及设施，建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员，以提高公司苏州设施的非临床研究产能。约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求。约39%将用于在广州及重庆建设新设施，雇佣经验丰富的专业人员，及发展尖端技术，进一步扩大公司于中国的设施网络及服务能力。约5%拓展及深化公司的综合合同研究组织服务，特别着重于进一步扩展公司的临床试验及相关服务。约20%为合适的专注于非临床研究的合同研究组织，专注于临床试验的合同研究组织及中国及海外的实验模型生产设施的潜在收购提供资金，以于未来一至三年内进一步实施公司拓宽药物研发价值链上的综合服务范围并拓展海外布局的策略。约10%将用于营运资金及一般企业用途。","news_type":1,"symbols_score_info":{"603127":0.9,"06127":0.9,"000860.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
